Alpha 2.0
Login Register
» Journals » Int J Clin Pharmacol Ther

International Journal of Clinical Pharmacology and Therapeutics

The International Journal of Clinical Pharmacology and Therapeutics is a reputable scholarly publication dedicated to advancing the understanding and application of clinical pharmacology and therapeutics. It provides a platform for researchers, clinicians, and pharmacologists to share their latest findings, innovative approaches, and evidence-based practices in drug therapy, pharmacokinetics, drug interactions, and therapeutic interventions. This journal serves as a valuable resource for healthcare professionals and researchers seeking to enhance patient care and optimize drug therapy outcomes
Details
Abbr. Int J Clin Pharmacol Ther
Start 1994
End Continuing
Frequency Monthly
p-ISSN 0946-1965
Country Germany
Language English
Specialty Pharmacology
Metrics
h-index / Ranks: 4869 73
SJR / Ranks: 12476 261
CiteScore / Ranks: 11103 1.80
JIF / Ranks: 7093 0.8
Recent Articles
1.
Liver dysfunction and long-acting aripiprazole: The importance of tolerability assessment
Hokama N, Ota K, Shiohira H, Takaesu Y, Nakamura K
Int J Clin Pharmacol Ther . 2025 Mar; PMID: 40063982
No abstract available.
2.
Prediction of hyperkalemia occurrence in patients using co-trimoxazole: Clinical adjustment of a Markov model
Watanabe F, Hirai T, Shiraishi C, Tasaka K, Iwamoto T, Hanada K
Int J Clin Pharmacol Ther . 2025 Mar; PMID: 40063981
Objective: Predicting the occurrence of hyperkalemia in patients undergoing co-trimoxazole treatment for Pneumocystis pneumonia is critical. However, other factors besides drug exposure affect serum potassium levels, and various interventions are...
3.
Cost-utility analysis of pembrolizumab versus nivolumab in the treatment of metastatic colorectal cancer from the perspective of the healthcare payer
Lu Z, Huang X, Ou Y, Wang Q, Tan Q
Int J Clin Pharmacol Ther . 2025 Mar; PMID: 40063980
Background: Colorectal cancer (CRC) is a malignant tumor with the third highest incidence worldwide. The comprehensive economic evaluation of programmed cell death protein-1 inhibitors in China, however, has not yet...
4.
Alleviation of renal ischemia-reperfusion injury by quercetin, kaempferol, and luteolin in Shiwei Hezi pill (SHP): Network pharmacology and molecular docking analysis of a traditional Tibetan herbal agent
Gomchok D, Yang H, Wuren T
Int J Clin Pharmacol Ther . 2025 Mar; PMID: 40035402
Objective: The aim of the study was to utilize a systematic network pharmacology approach to explore the active components, targets, and pathways associated with the efficacy of Shiwei Hezi pill...
5.
Differentiation of bone marrow mesenchymal stem cells modulated by Bushen Tian Sui decoction via the TGF-β1-Smad2/3 signaling pathway: In vitro evidence and potential clinical application in delayed fracture healing
Xiong W, Li B, Chen J, Shao Z, Sun W, Li S, et al.
Int J Clin Pharmacol Ther . 2025 Feb; PMID: 40013965
Background: Bone-related disorders pose significant challenges in clinical practice. Bone marrow mesenchymal stem cells (BMSCs), as multipotent stem cells, play a pivotal role in bone regeneration. The TGF-β1-Smad2/3 signaling pathway...
6.
Bisphosphonates in combination with alendronate sodium increase bone mineral density and modulate IL-6, TNF-α, and IGF-1 in patients with osteoporosis
Gu X, Zhang L, Chen X, Kong L
Int J Clin Pharmacol Ther . 2025 Feb; PMID: 40013964
Objective: To assess the effects of bisphosphonates (zoledronic acid injection) plus alendronate sodium on bone mineral density (BMD) and levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and insulin-like growth...
7.
Evidence for a loss of analgesia when hydromorphone administered in combination with hange-shashin-to: Enterohepatic circulation and β-glucuronidase inhibition
Ozaki M, Yamagata H, Matsui H, Okada N, Matsumoto M, Nagano H, et al.
Int J Clin Pharmacol Ther . 2025 Feb; PMID: 40013963
No abstract available.
8.
Network pharmacology and experimental analysis of Yudantong decoction, a multi-immunomodulator for the treatment of intractable cholestatic liver disease: Identification of active agents, molecular targets, and mechanisms of action
Wu X, Hou L, Liu J, Hao J, Liu C, Hu Y, et al.
Int J Clin Pharmacol Ther . 2025 Feb; PMID: 40013962
Background: Yudantong decoction (YDTD) is a therapeutic prescription for cholestatic liver disease (CLD) and is clinically effective in our medical institution. However, the exact constituents and mechanisms of YDTD in...
9.
Cardiovascular safety profile of JAK inhibitors and ethnic factors in Asians: A signal detection study using the Global ICSR (WHO-UMC VigBase) database
Nam W, Bae J, Oh J, Shin J, Kim H
Int J Clin Pharmacol Ther . 2025 Feb; PMID: 40013961
Objective: This study aimed to detect cardiovascular disease-related signals using Global Individual Case Safety Report data on JAK inhibitors. Materials And Methods: A signal detection study was conducted using the...
10.
Niraparib-related severe refractory thrombocytopenia in ovarian cancer patients receiving paclitaxel/carboplatin chemotherapy: A report on three cases
Chen M, Zhou L, Yang H, Wang M
Int J Clin Pharmacol Ther . 2025 Feb; PMID: 39928104
A characteristic toxicity of niraparib is a decrease in blood platelets (PLT), with an incidence of ~ 34% for grades 3 - 4 conditions. However, exceedingly severe cases have been...